FDA Confirms Ort-Flx Contains Undeclared Diclofenac, Dexamethasone, and Methocarbamol

Laboratory analysis by FDA has confirmed that Ort-Flx, a product marketed for pain, arthritis, and allergies through online retailers including eBay and select brick-and-mortar stores, contains three undeclared active pharmaceutical ingredients, a finding that carries direct implications for supply chain integrity and adverse event reporting obligations across the industry.

Testing identified diclofenac, dexamethasone, and methocarbamol, none of which appear on the product label. Diclofenac, an NSAID, carries well-documented cardiovascular and gastrointestinal risk profiles, including elevated risk of myocardial infarction, stroke, and gastrointestinal perforation. Dexamethasone, a corticosteroid, presents immunosuppressive effects alongside risks of hyperglycemia, myopathy, and psychiatric disturbance. Methocarbamol, a centrally acting muscle relaxant, introduces CNS depression risks including drowsiness, dizziness, and hypotension. Patients currently using Ort-Flx face compounded risk if any of these agents interact with concurrent medication regimens.

For QA directors and regulatory affairs leads, the enforcement action reinforces a persistent gap in the dietary supplement and OTC landscape: products represented as natural formulations routinely evade pre-market API screening. FDA has explicitly acknowledged it cannot test all products marketed as dietary supplements for hidden ingredients, placing downstream vigilance obligations on healthcare professionals and, by extension, on pharmacovigilance functions within regulated manufacturers who may encounter these products through MedWatch signal monitoring.

MedWatch reporting, via the Online Voluntary Reporting Form or by fax to 1-800-FDA-0178, remains the primary mechanism for adverse event capture on products of this type. Regulatory teams should ensure internal SOPs account for supplement-related adverse event signals, particularly where undeclared APIs overlap with monitored drug classes already within a company's pharmacovigilance scope.

The broader pattern is consistent with FDA's ongoing Medication Health Fraud program, which has repeatedly flagged pain relief, sexual enhancement, weight loss, and bodybuilding products as high-risk categories for undeclared drug ingredients. Ort-Flx fits the established profile: an all-natural positioning, multi-channel retail distribution, and a label that bears no relationship to the confirmed chemical composition.

Corticosteroid withdrawal risk adds a clinical urgency dimension: patients who have used Ort-Flx for extended periods require supervised discontinuation, as abrupt cessation of undeclared dexamethasone exposure carries its own adverse event potential.

The MedWatch reporting window for adverse events linked to Ort-Flx remains open, and signal volume from this notification will inform whether FDA escalates to a formal recall or import alert action.

Source: U.S. Food and Drug Administration, Medication Health Fraud Notifications, via FDA.gov, October 28, 2026.